Dandagi P M, Mastiholimath V S, Gadad A P, Kulkarni A R, Konnur B K
Department of Pharmaceutics, K. L. E. S's College of Pharmacy, J. N. M. C. Campus, Nehru Nagar, Belgaum-590 010, India.
Indian J Pharm Sci. 2009 Jul;71(4):464-8. doi: 10.4103/0250-474X.57303.
Mebeverine hydrochloride is known to suffer from extensive first pass effect. In an attempt to improve its oral bioavailability and possibility to restrict its absorption only to the colon, mebeverine microspheres were prepared by emulsion solvent evaporation method. Four formulations were prepared with varying drug and polymer ratio. These formulations were subjected to various evaluation parameters like percent practical yield, entrapment efficiency, particle size, in vitro drug release, in vivo activity. Practical yield of the microspheres was up to 89.59% with encapsulation efficiency up to 79.4%. Scanning electron microscopy confirmed that the microsphere structures were smooth, spherical, and discrete and the particles were of the size range 200 to 300 mum. In vitro release of the drug showed biphasic release pattern with non-Fickian diffusion release in 12 h. On the basis of drug content, particle size, in vitro release and in vivo studies, formulation F-3 was found to be optimal. Antiirritable bowel syndrome activity was performed in colorectal distention in rat, which is a model for constipation-induced irritable bowel syndrome. The formulations F-2 and F-3 showed significant effect in fecal output when compared to the control as well as the marketed preparation in the constipation-induced irritable bowel syndrome in rats.
已知盐酸美贝维林存在广泛的首过效应。为提高其口服生物利用度并使其吸收仅局限于结肠,采用乳化溶剂蒸发法制备了美贝维林微球。制备了四种药物与聚合物比例不同的制剂。对这些制剂进行了各种评价参数的测定,如实际收率百分比、包封率、粒径、体外药物释放、体内活性等。微球的实际收率高达89.59%,包封效率高达79.4%。扫描电子显微镜证实微球结构光滑、呈球形且离散,粒径范围为200至300μm。药物的体外释放呈现双相释放模式,在12小时内为非菲克扩散释放。基于药物含量、粒径、体外释放和体内研究,发现制剂F-3是最佳的。在大鼠结肠扩张模型中进行了抗肠易激综合征活性研究,该模型用于模拟便秘诱导的肠易激综合征。与对照组以及市售制剂相比,制剂F-2和F-3在大鼠便秘诱导的肠易激综合征中对粪便排出量显示出显著效果。